Characteristic peaks of the individual excipients were also retained; also no new peak
was found in drug-loaded mixture of the excipients to be formulated in liquisolids. This indicates that there is no interaction between the drug and excipients. Figure 4 (a) FTIR spectrum of Olmesartan Medoxomil. (b) FTIR spectrum of selleck liquisolid mixture. 3.6. Quality Control Studies 3.6.1. Content Uniformity, Inhibitors,research,lifescience,medical Hardness, Friability, and Disintegration Tests All prepared tablets complied with the pharmacopoeial required specifications for the weight variation and content uniformity tests. Results of hardness, friability, and disintegration time are represented in Table 4. Hardness test showed an average hardness of liquisolid tablets ranging from 4.0 ± 0.73 to 6.0 ± 1.1Kg/cm2. Another measure of tablets strength is friability. Conventional compressed tablets that lose less than 1% of their weight Inhibitors,research,lifescience,medical are generally considered acceptable. The percentage friability for all formulations was below 1%, indicating that the friability is within the prescribed limits. This indicates acceptable resistance was shown by liquisolid tablets to withstand handling. Disintegration time was found to be in the range of 1.5 ± 0.21 to 3.2 ± 0.27min for liquisolid preparations intended for immediate drug release characteristics. Table 4 Physical
properties of liquisolid compacts. 3.7. In Vitro Dissolution Studies The dissolution Inhibitors,research,lifescience,medical profiles of the liquisolid tablets for fast release formulations and conventional tablets of olmesartan tablets are shown in Figures 5(a) and 5(b). The percentage drug released after 5min (Q) and the time required for the release of 50% of the drug (t) were determined and are shown in Table 5. Additionally, 50 percent dissolution efficiency Inhibitors,research,lifescience,medical (%DE) was calculated from the area under each dissolution curve at time “t”, measured using the trapezoidal rule, and expressed as a percentage of the area of rectangle described by 100% dissolution at the same time they were also calculated. Figure Inhibitors,research,lifescience,medical 5 (a) In vitro dissolution profile for liquisolid compacts with 40% [w/w] drug concentration.
(b) In vitro dissolution profile for liquisolid compacts with 20% [w/w] drug concentration. Table 5 Dissolution parameters of optimized liquisolid compacts and conventional tablets of Olmesartan medoxomil. From the dissolution profiles, Resminostat it can be seen that all liquisolid formulations significantly improved drug dissolution compared to conventional tablets. Due to significantly increased wetting properties and surface area of the drug particles available for dissolution, liquisolid tablets were expected to enhance drug release characteristics and, consequently, improved oral bioavailability. As shown in Table 5, LSA 15 showed prompt drug release with Q5 value of 44.48% compared to only 11.62% for conventional tablets. Time required for 50% drug release was found to be less than 5 minutes.